The Medullary Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Medullary Thyroid Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued products.
GlobalData tracks 43 drugs in development for Medullary Thyroid Cancer by 36 companies/universities/institutes. The top development phase for Medullary Thyroid Cancer is phase ii with 17 drugs in that stage. The Medullary Thyroid Cancer pipeline has 34 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Medullary Thyroid Cancer pipeline products market are: Jiangsu Hengrui Medicine, University of Pisa and University of Arkansas for Medical Sciences.
The key targets in the Medullary Thyroid Cancer pipeline products market include Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor, and Vascular Endothelial Growth Factor Receptor 2.
The key mechanisms of action in the Medullary Thyroid Cancer pipeline product include Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor with 17 drugs in Phase III. The Medullary Thyroid Cancer pipeline products include nine routes of administration with the top ROA being Oral and eight key molecule types in the Medullary Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Medullary Thyroid Cancer overview
Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine neoplasia type 2 (MEN2). Symptoms of MTC may include a lump in the neck, hoarseness, diarrhea, and flushing. The main treatment for MTC is surgery to remove the thyroid gland and sometimes the nearby lymph nodes. Other treatments, such as radiation or medication, may be used depending on the stage and spread of the cancer. Early detection and treatment of MTC can improve the prognosis and quality of life of patients.
For a complete picture of Medullary Thyroid Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
